Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Biopixlar, a 3D single-cell bioprinting platform that produces single cell arrays to organoids and complex tissues; Nexocyte, a platform for universal tissue production; and Biopixlar AER, a single-cell bioprinting platform that fits into a biosafety cabinet. Fluicell AB (publ) was incorporated in 2012 and is based in Mölndal, Sweden.…
Fluicell aktie • FLUI
Fluicell (STO: FLUI) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 21.10 SEK on 20 November 2026, up 64.8% over 52 weeks. Its 52-week range is 7.650 SEK to 67.20 SEK: the price is 68.6% below the high and 175.8% above the low.
At a market capitalisation of 28.99M SEK, it trades at 10.4 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 69% for FLUI.
Fluicell reports return on equity of -76.4%, an operating margin of 18.6% and revenue up 224.5% year over year.
It holds more cash than debt, a net cash position of 718.00K SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.
No upcoming events tracked.